SCHEMBL14711784

SCHEMBL14711784

Cc1cc2c(-c3ccc(-c4onc(C)c4NC(=O)OC(C)c4ccccc4)cc3)ccc(CC(=O)O)c2[nH]1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 16/20 0.65
LPAR3 Q9UBY5 10/20 0.61
ABCC3 O15438 1/20 0.54
ABCC4 O15439 1/20 0.54
ABCB11 O95342 1/20 0.54
CYP2C8 P10632 1/20 0.54
CYP2C9 P11712 1/20 0.54
ABCB4 P21439 1/20 0.54
ABCC2 Q92887 1/20 0.54
SLCO1B3 Q9NPD5 1/20 0.54
SLCO1B1 Q9Y6L6 1/20 0.54
LPAR2 Q9HBW0 2/20 0.53
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
F9 P00740 1/20 0.32
F10 P00742 1/20 0.32
PLAU P00749 1/20 0.32
HRH1 P35367 1/20 0.32
KCNA3 P22001 1/20 0.32
CIT O14578 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14711785 0.90 LPAR1 (0.68) LPAR1LPAR3ABCC3ABCC4ABCB11
SCHEMBL14711806 0.89 LPAR1 (0.70) LPAR1LPAR3ABCC3ABCC4ABCB11
SCHEMBL14710461 0.86 LPAR1 (0.46) LPAR1LPAR3ABCC3ABCC4ABCB11
SCHEMBL2295361 0.84 LPAR1 (0.78) LPAR1LPAR3ABCC3ABCC4ABCB11
SCHEMBL2295364 0.84 LPAR1 (0.78) LPAR1LPAR3ABCC3ABCC4ABCB11
SCHEMBL14711789 0.84 LPAR1 (0.67) LPAR1LPAR3ABCC3ABCC4ABCB11
SCHEMBL14709998 0.83 LPAR1 (0.65) LPAR1LPAR3ABCC3ABCC4ABCB11
SCHEMBL14710036 0.82 LPAR1 (0.69) LPAR1LPAR3ABCC3ABCC4ABCB11
SCHEMBL14710003 0.82 LPAR1 (0.68) LPAR1LPAR3ABCC3ABCC4ABCB11
SCHEMBL14711781 0.81 LPAR1 (0.71) LPAR1LPAR3ABCC3ABCC4ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
WO-2013025733-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 LPAR1 1/4885LPAR3 5/4885ABCC3 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.